A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer

Cancer Biotherapy and Radiopharmaceuticals - Tập 24 Số 2 - Trang 175-180 - 2009
J Horti1, Anders Widmark2, Arnulf Stenzl3, Miriam Hatsue Honda Federico4, Raymond P. Abratt5, Nick Sanders6, G. Pover7, I. Bodrogi1
1National Institute of Oncology, Budapest, Hungary
2Umea University Hospital, Umea, Sweden
3University of Tuebingen, Tuebingen, Germany
4Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil
5New Groote Schuur Hospital, Cape Town, South Africa.
6AstraZeneca, Loughborough, UK
7AstraZeneca, Macclesfield, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1038/sj.bjc.6602603

Wedge SR, 2002, Cancer Res, 62, 4645

10.1517/13543784.16.2.239

Weidner N, 1993, Am J Pathol, 143, 401

Bok RA, 2001, Cancer Res, 61, 2533

George DJ, 2001, Clin Cancer Res, 7, 1932

Di Lorenzo G, 2002, Clin Cancer Res, 8, 3438

10.1002/pros.20715

10.1158/1078-0432.CCR-07-1257

10.1007/s00432-007-0247-4

10.1056/NEJMoa040720

10.1200/JCO.2006.10.5122

10.1200/JCO.2005.01.149

10.1200/JCO.2006.06.8197

10.1056/NEJMoa041318

10.1186/1471-2407-7-142

10.1200/JCO.2007.11.4769

10.1200/JCO.2005.08.156

10.1093/jnci/djj129

10.1038/nrc2351

10.1200/JCO.2007.12.4487

10.1038/sj.bjc.6604064

10.1007/s10637-007-9050-y

10.1093/annonc/mdm554

10.1111/j.1464-410X.2007.07121.x

10.1093/annonc/mdi247

10.1097/01243894-200611000-00014

10.1200/JCO.2006.07.2066

10.1016/S1470-2045(08)70003-2

Thông tin
Thông tin xuất bản

Cancer Biotherapy and Radiopharmaceuticals

Tập 24 Số 2

175-180

Thông tin tác giả